Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
complement inhibitor |
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AA54
|
| gptkbp:brand |
gptkb:Empaveli
gptkb:Aspaveli |
| gptkbp:CASNumber |
2028263-64-7
|
| gptkbp:chemicalClass |
peptide
|
| gptkbp:developer |
gptkb:Apellis_Pharmaceuticals
|
| gptkbp:drugClass |
immunosuppressant
|
| gptkbp:hasMolecularFormula |
C192H296N52O64
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pegcetacoplan
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
C3 complement inhibitor
|
| gptkbp:pregnancyCategory |
unknown
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
diarrhea
abdominal pain injection site reaction infections |
| gptkbp:target |
gptkb:complement_component_3_(C3)
|
| gptkbp:UNII |
6QY1D9Y4F4
|
| gptkbp:usedFor |
gptkb:geographic_atrophy
gptkb:paroxysmal_nocturnal_hemoglobinuria |
| gptkbp:bfsParent |
gptkb:Apellis_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|